Mangalam Financial Statements From 2010 to 2025

Stocks . India . 
Stock . Mangalam Drugs And
MANGALAM   79.79  0.32  0.40%   
Mangalam Drugs financial statements provide useful quarterly and yearly information to potential Mangalam Drugs And investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Mangalam Drugs financial statements helps investors assess Mangalam Drugs' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Mangalam Drugs' valuation are summarized below:
Gross Profit
1.2 B
Profit Margin
0.0088
Market Capitalization
1.7 B
Enterprise Value Revenue
0.5698
Revenue
3.6 B
We have found eighty-five available fundamental ratios for Mangalam Drugs, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Mangalam Drugs last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Mangalam Drugs Total Revenue

2.59 Billion

Check Mangalam Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangalam Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 176.9 M, Interest Expense of 168 M or Selling General Administrative of 471.8 M, as well as many indicators such as . Mangalam financial statements analysis is a perfect complement when working with Mangalam Drugs Valuation or Volatility modules.
  
This module can also supplement various Mangalam Drugs Technical models . Check out the analysis of Mangalam Drugs Correlation against competitors.

Mangalam Drugs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.1 B3.8 B2.2 B
Slightly volatile
Short and Long Term Debt Total2.2 B1.2 B2.2 B
Slightly volatile
Other Current Liabilities72.1 M84.6 M75.3 M
Slightly volatile
Total Current Liabilities2 B1.9 B1 B
Slightly volatile
Total Stockholder Equity841.8 M1.6 B885.7 M
Slightly volatile
Property Plant And Equipment Net884.7 M1.5 B912.3 M
Slightly volatile
Net Debt682.2 M1.2 B698.9 M
Slightly volatile
Cash10.3 M13.7 M10.2 M
Slightly volatile
Non Current Assets Total950 M1.8 B999.5 M
Slightly volatile
Non Currrent Assets Other1 M1.1 M14.4 M
Slightly volatile
Cash And Short Term Investments16.9 M13.7 M16.9 M
Slightly volatile
Net Receivables426.9 M321.4 M402.8 M
Slightly volatile
Common Stock Shares Outstanding16 M18.2 M15.2 M
Slightly volatile
Liabilities And Stockholders Equity2.1 B3.8 B2.2 B
Slightly volatile
Non Current Liabilities Total273.1 M304.6 M318.9 M
Very volatile
Inventory1.5 B1.4 B756.4 M
Slightly volatile
Other Current Assets147.7 M267.1 M137.6 M
Pretty Stable
Other Stockholder Equity446 M382.2 M436.9 M
Pretty Stable
Total Liabilities1.2 B2.3 B1.3 B
Slightly volatile
Total Current Assets1.1 B2 B1.2 B
Slightly volatile
Common Stock159.5 M182 M150.7 M
Slightly volatile
Accounts Payable426.8 M760.9 M413.7 M
Slightly volatile
Short Term Debt525.3 M1 B514.3 M
Slightly volatile
Short Term Investments1 M1.1 M35.9 M
Pretty Stable
Other Liabilities117.7 M193.3 M97.9 M
Slightly volatile
Net Tangible Assets973.9 M1.5 B837.3 M
Slightly volatile
Long Term Debt114.2 M120.2 M1.2 B
Very volatile
Short and Long Term Debt509.9 M857.9 M548.9 M
Very volatile
Property Plant Equipment14.2 B13.5 B4.3 B
Slightly volatile
Long Term Debt Total3.3 B3.4 B3 B
Slightly volatile
Intangible Assets344.4 M328 M132.5 M
Slightly volatile
Current Deferred Revenue63.7 M53.6 M46.5 M
Slightly volatile
Net Invested Capital2.1 B2.6 B1.9 B
Slightly volatile
Long Term Investments1.9 M2.2 M2.4 M
Slightly volatile
Net Working Capital273.2 M137.3 M242.2 M
Very volatile
Capital Stock126.6 M142.5 M155.3 M
Slightly volatile
Capital Lease Obligations90.8 M121.2 M49.9 M
Slightly volatile
Property Plant And Equipment Gross1.3 B1.2 B1.6 B
Slightly volatile
Cash And Equivalents778.1 M1.1 B463 M
Slightly volatile
Capital Surpluse144.5 M162.5 M177.2 M
Slightly volatile
Good Will800900981
Slightly volatile

Mangalam Drugs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization176.9 M168.5 M80.6 M
Slightly volatile
Selling General Administrative471.8 M449.3 M128.6 M
Slightly volatile
Selling And Marketing Expenses263.6 M251.1 M80.5 M
Slightly volatile
Total Revenue2.6 B4.2 B2.7 B
Slightly volatile
Gross Profit205.5 M216.3 M606.8 M
Slightly volatile
Other Operating Expenses2.4 B4.2 B2.5 B
Slightly volatile
Cost Of Revenue4.2 B4 B2.2 B
Slightly volatile
Total Operating Expenses177.2 M186.6 M438.1 M
Slightly volatile
Research Development22.5 M37.6 M20.3 M
Slightly volatile
Interest Income1 M1.1 M287.6 M
Slightly volatile
Reconciled Depreciation105.2 M168.5 M87.7 M
Slightly volatile

Mangalam Drugs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow32.4 M30.8 M12 M
Slightly volatile
Depreciation62.4 M86.2 M64 M
Slightly volatile
Capital Expenditures145.7 M136.1 M140.8 M
Slightly volatile
End Period Cash Flow10.3 M13.6 M10.1 M
Slightly volatile
Other Cashflows From Investing Activities45.3 K47.7 K676.3 K
Very volatile
Sale Purchase Of Stock8.1 M8.5 M35 M
Slightly volatile
Change To Netincome128.1 M159.8 M116 M
Slightly volatile
Dividends Paid27.9 M47.4 M23.5 M
Slightly volatile

Mangalam Fundamental Market Drivers

Cash And Short Term Investments11.9 M

About Mangalam Drugs Financial Statements

Mangalam Drugs stakeholders use historical fundamental indicators, such as Mangalam Drugs' revenue or net income, to determine how well the company is positioned to perform in the future. Although Mangalam Drugs investors may analyze each financial statement separately, they are all interrelated. For example, changes in Mangalam Drugs' assets and liabilities are reflected in the revenues and expenses on Mangalam Drugs' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Mangalam Drugs And. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue53.6 M63.7 M
Total Revenue4.2 B2.6 B
Cost Of Revenue4 B4.2 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
SSentinelOne
GMGeneral Motors

Other Information on Investing in Mangalam Stock

Mangalam Drugs financial ratios help investors to determine whether Mangalam Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mangalam with respect to the benefits of owning Mangalam Drugs security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY